Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Anemia Drugs Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The anemia drugs market has experienced substantial growth in recent years. It is anticipated to expand from $15.77 billion in 2025 to $16.96 billion in 2026, at a compound annual growth rate (CAGR) of 7.5%. This historical expansion can be attributed to factors such as the prevalence of iron deficiency, the increasing incidence of chronic kidney disease, the extensive use of hospital transfusions, the occurrence of maternal anemia, and various dietary deficiencies.
The anemia drugs market size is projected to experience substantial growth over the coming years. It is anticipated to reach $22.69 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. This expansion during the forecast period is attributable to several factors, including an aging population, the management of chronic disease anemia, the adoption of injectable iron, the expansion of home healthcare, and preventive supplementation. Noteworthy trends for the forecast period comprise the increasing use of erythropoiesis-stimulating agents, the development of intravenous iron therapy, the broadening of home-based anemia management, a heightened focus on chronic disease anemia, and a shift towards combination supplement therapy.
Get A Free Sample Report With In-Depth Market Insights:
Anemia Drugs Market Expansion Drivers: What’s Shaping Future Growth?
A growing emphasis on personalized medicine is anticipated to boost the expansion of the anemia drugs market moving forward. This medical approach customizes treatment and healthcare choices according to an individual’s unique genetic profile, lifestyle, and environmental factors. The heightened attention on personalized medicine stems from progress in genomic sequencing, enabling more accurate detection of individual genetic variations connected to diseases and how patients respond to treatments. It aids in the development of anemia drugs by facilitating customized treatments derived from individual genetic profiles, thereby enhancing drug effectiveness and reducing unwanted side effects, which leads to improved patient results. As an example, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit organization, revealed that the U.S. Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for rare disease patients in 2023, marking a considerable rise from 6 approvals in 2022. Consequently, the heightened emphasis on personalized medicine is a key driver for the expansion of the anemia drugs market.
Anemia Drugs Market Segment Outlook: Which Categories Are Growing Fastest?
The anemia drugs market covered in this report is segmented –
1) By Drug Type: Dietary Supplements, Medicines
2) By Therapy Type: Oral Iron Therapy, Red Blood Cell Transfusion, Parental Iron Therapy, Other Therapy Types
3) By Anemia Type: Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia, Other Anemia Types
4) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
5) By End-User: Clinic, Healthcare, Home Healthcare
Subsegments:
1) By Dietary Supplements: Iron Supplements, Vitamin B12 Supplements, Folic Acid Supplements, Multivitamin And Mineral Supplements
2) By Medicines: Erythropoiesis-Stimulating Agents (ESAs), Iron Chelating Agents, Corticosteroids, Immunosuppressants, Luspatercept And Related Agents
Anemia Drugs Market Strategic Trends: What Defines The Next Growth Phase?
Companies operating within the anemia drugs market are primarily directing their efforts towards developing innovative medications, such as oral HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitors), with the aim of refining iron metabolism and stimulating red blood cell production for more effective treatments for anemia. Oral HIF-PHI refers to a group of orally administered drugs that specifically target and hinder prolyl hydroxylase enzymes, which are key regulators of the hypoxia-inducible factor (HIF) pathway. As an illustration, GSK plc, a pharmaceutical firm based in the UK, unveiled Jesduvroq in February 2023. This treatment is intended to improve red blood cell formation and manage anemia in adult individuals affected by chronic kidney disease. This advanced anemia drug system features enhanced iron metabolism, increased red blood cell production, and individualized therapeutic approaches. Jesduvroq proves highly effective, stimulating red blood cell generation and addressing anemia in chronic kidney disease patients by optimizing iron metabolism, leading to superior treatment outcomes.
Anemia Drugs Market Leading Companies And Competitive Benchmarking
Major companies operating in the anemia drugs market are Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Fresenius SE & Co. KGaA, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Biocon Limited, Akebia Therapeutics Inc., Apellis Pharmaceuticals Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Covis Pharma GmbH, AdvaCare Pharma LLC, BioLineRx Ltd., Bluebird Bio Inc.
View The Full Anemia Drugs Market Report:
Anemia Drugs Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the anemia drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anemia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model